<DOC>
	<DOCNO>NCT01357486</DOCNO>
	<brief_summary>The incidence Hepatocellular Carcinoma ( HCC ) currently increase Europe France 2 / 3 patient , eligible curative treatment time diagnosis . The palliative management patient advance symptomatic disease complex require treatment combine anti-tumor activity safety patient impaired liver function . Sorafenib standard care palliative setting , benefit sorafenib patient alter liver function uncertain . The aim trial study interest sorafenib patient HCC impair liver function compare pravastatin ( drug anti-tumoral activity HCC ) combination sorafenib/pravastatin best supportive care ( usually use patient ) .</brief_summary>
	<brief_title>Palliative Treatment Hepatocellular Carcinoma Patient With CHILD B Cirrhosis</brief_title>
	<detailed_description>The incidence Hepatocellular Carcinoma ( HCC ) currently increase Europe France . It almost always occur liver disease 80 90 % case , least France , liver cirrhosis . If curative treatment may propose `` small '' HCC ( transplantation , resection , percutaneous destruction ) , 2 / 3 patient , represent nearly 4,000 new case per year France , eligible treatment . The palliative management patient advance symptomatic disease complex require treatment combine anti-tumor activity safety patient impaired liver function . Indeed , case palliative treatment HCC apply patient alter liver function ( stage B Child-Pugh classification ) . To date , propose treatment France patient base best supportive care . The objective study assess interest situation 2 molecule - take alone combination : - Sorafenib , reference palliative treatment advance hepatocellular carcinoma ( Stage C BCLC classification ) . Yet safety efficacy sorafenib patient alter liver function ( CHILD B ) clearly define use remain discouraged French recommendation patient . - Pravastatin whose interest palliative treatment HCC suggest several phase II study good safety profile cirrhotic patient . In French multicenter open randomize study , 160 patient include 4 arm ( 40/arms ) : sorafenib , pravastatin , pravastatin + sorafenib , supportive care . The aim phase II multicenter study select two best arm Phase III study order identify reference treatment palliative situation .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male female subject &gt; 18 year age Hepatocellular carcinoma histologically diagnose case inability perform histology non invasive radiological criterion presence know cirrhosis : ( ) Hepatic lesion measure 1 2 cm diameter : CTscan + MRI ( eventually Ultrasound contrast ) : HCC diagnose contrast uptake arterial phase rapid wash venous /late phase two image technique . ( ii ) Hepatic lesion diameter &gt; 2 cm : CTscan MRI +alpha fetoprotein : HCC diagnose contrast uptake arterial phase rapid wash venous /late phase alpha fetoprotein &gt; 200Âµg/L Patient eligible curative treatment ( transplantation , resection , destruction percutaneous chemoembolization ) HCC still evolve failure specific treatment Score CHILD B ECOG performance status 0/1/2 Score BCLC B C Adequate haematologic function haemoglobin &gt; 8 g/dl , platelet count &gt; 50000x 109/L , absolute neutrophil count &gt; 1000 / mm3 Creatinine &lt; 2 time upper limit normal Written inform consent Any condition unstable could jeopardize safety subject compliance study Pregnancy Myocardial infarction le 6 month , uncontrolled hypertension , congestive heart failure ( NYHA class &gt; 2 ) , anti arrhythmic treatment betablockers digoxin Digestive bleeding within 30 day inclusion Hepatic transplantation Patients receive receive statine le 6 month HCC diagnostic Prior use sorafenib Psychiatric illness/social situation would limit compliance study requirement . Previous concurrent cancer , except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor . Any cancer curatively treat &gt; 5 year prior entry permit Known suspect history allergy sorafenib pravastatin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>CHILD B</keyword>
	<keyword>palliative management</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Pravastatin</keyword>
</DOC>